Oxypoint breekt met innovatieve zuurstoftherapie door in Europa

Oxypoint NV signs distribution deal with Linde Group

Oxypoint signe un contrat de distribution avec Linde Group

Antwerp, - Oxypoint NV, the Belgian pioneer in hospital-based oxygen therapy, today announces it has signed a framework distribution deal with Linde plc. With this distribution deal, Linde will become a distributor of Oxypoint’s patented O2COMFORTTM flowmeter in 6 European countries.

Innovatie in zuurstoftherapie

The fact that Linde, the world’s largest industrial gases company, signs a distribution contract with Oxypoint represents an enormous pat on the back for us. Of course we cannot be compared in size with Linde, but having a top DAX 30 stock-market company ask us to be allowed to sell our unique O2COMFORTTM flowmeter, underpins our credibility.” says Wouter Van Roost, CEO.


Back in 2012, when we convinced the first hospitals to buy our flowmeter, we would have never imagined that we would be in this position today” adds Philip Hendrickx, COO and founder. “The framework agreement with Linde adds a sizeable player to our commercial presence in Europe.


“Our priority is to provide products and services which allow our customers to treat their patients in the safest, most efficient way. O2Comfort is an innovative product which allows safe and efficient oxygen therapy while also increasing patient comfort,”, said Matthias Bause, Business Development Manager Healthcare, Linde.


Oxypoint is a young innovative company, a spin-off of the University of Antwerp and winner of various innovation-awards. Mid 2018, management raised 3.8 mio. in a Series A capital round led by Participatie Maatschappij Vlaanderen (PMV) and a Luxembourg family-fund. The capital raised served to expand the commercial activities and start new R&D projects. Oxypoint is based in Antwerp.



Wouter Van Roost - CEO wouter.vanroost@oxypoint.eu  +32. 478 99 52 06

Philip Hendrickx - FOUNDER -  philip.hendrickx@oxypoint.eu +32. 496 03 27 76


Back to overview